{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Akshintala S"],"funding":["Intramural NIH HHS","National Cancer Institute","NCI NIH HHS","USC Norris Comprehensive Cancer Center"],"pagination":["3329-3339"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10529967"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(17)"],"pubmed_abstract":["Purpose
Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown to mediate IGF type 1 receptor (IGF-1R) antibody acquired resistance, and cotargeting IGF-1R and YES resulted in sustained responses in murine RMS models. We conducted a phase I trial of the anti-IGF-1R antibody ganitumab combined with dasatinib, a multi-kinase inhibitor targeting YES, in patients with RMS (NCT03041701).Patients and methods
Patients with relapsed/refractory alveolar or embryonal RMS and measurable disease were eligible. All patients received ganitumab 18 mg/kg intravenously every 2 weeks. Dasatinib dose was 60 mg/m2/dose (max 100 mg) oral once daily ["],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma."],"pmcid":["PMC10529967"],"funding_grant_id":["P30 CA014089","ZIA BC011745","5P30CA014089-45"],"pubmed_authors":["Widemann BC","Heske CM","Gross AM","Lei H","Bernstein D","Palacio-Yance I","Mascarenhas L","Pan A","Miettinen MM","Shern JF","Steinberg SM","Kaplan RN","Herrera KR","Dombi E","Helman LJ","Akshintala S","Navid F","Yohe ME","Chen HX","Sundby RT","Derdak J","Glod JW"],"additional_accession":[]},"is_claimable":false,"name":"Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.","description":"Purpose
Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The SRC family member YES has been shown to mediate IGF type 1 receptor (IGF-1R) antibody acquired resistance, and cotargeting IGF-1R and YES resulted in sustained responses in murine RMS models. We conducted a phase I trial of the anti-IGF-1R antibody ganitumab combined with dasatinib, a multi-kinase inhibitor targeting YES, in patients with RMS (NCT03041701).Patients and methods
Patients with relapsed/refractory alveolar or embryonal RMS and measurable disease were eligible. All patients received ganitumab 18 mg/kg intravenously every 2 weeks. Dasatinib dose was 60 mg/m2/dose (max 100 mg) oral once daily [","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-04-29T14:09:23.181Z","creation":"2025-04-20T03:01:35.024Z"},"accession":"S-EPMC10529967","cross_references":{"pubmed":["37398992"],"doi":["10.1158/1078-0432.ccr-23-0709","10.1158/1078-0432.CCR-23-0709"]}}